Jay M. Moyes's most recent trade in BioCardia Inc. was a trade of 12,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioCardia Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2025 | 12,000 | 15,573 | - | - | Stock Option (right to buy) | |
| SINTX Tech Inc | Jay M. Moyes | Director | Purchase of securities on an exchange or from another person at price $ 3.59 per share. | 26 Aug 2025 | 3,000 | 3,000 (0%) | 0% | 3.6 | 10,756 | Common Stock |
| Puma biotech Inc | Jay M. Moyes | Director | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 13 Jun 2025 | 22,000 | 53,322 (0%) | 0% | 3.4 | 74,800 | Common Stock |
| Puma biotech Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 27,000 | 75,322 (0%) | 0% | 0 | Common Stock | |
| BioCardia Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2024 | 829 | 3,573 | - | - | Stock Option (right to buy) | |
| Puma biotech Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 27,000 | 48,322 (0%) | 0% | 0 | Common Stock | |
| Puma biotech Inc | Jay M. Moyes | Director | Sale of securities on an exchange or to another person at price $ 3.34 per share. | 13 Jun 2024 | 22,000 | 21,322 (0%) | 0% | 3.3 | 73,467 | Common Stock |
| Puma biotech Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 27,000 | 43,322 (0%) | 0% | 0 | Common Stock | |
| Puma biotech Inc | Jay M. Moyes | Director | Sale of securities on an exchange or to another person at price $ 3.45 per share. | 13 Jun 2023 | 22,000 | 16,322 (0%) | 0% | 3.5 | 75,970 | Common Stock |
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 51,800 | 51,800 | - | - | Stock Option (right to buy) | |
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 32,800 | 35,630 | - | 0 | Class A Common Stock | |
| Puma biotech Inc | Jay M. Moyes | Director | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 16 Jun 2022 | 22,858 | 38,322 (0%) | 0% | 2.6 | 60,370 | Common Stock |
| Puma biotech Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 27,000 | 61,180 (0%) | 0% | 0 | Common Stock | |
| BioCardia Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 12,434 | 28,789 | - | - | Stock Option (right to buy) | |
| Achieve Life Sciences Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 4,400 | 4,400 | - | - | Stock Option (right to buy) | |
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2022 | 168,275 | 168,275 | - | - | Stock Option (right to buy) | |
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | 19 Jul 2021 | 2,455 | 0 | - | - | Series A-2 Preferred Stock | ||
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | 19 Jul 2021 | 2,455 | 2,455 | - | - | Class A Common Stock | ||
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | 19 Jul 2021 | 375 | 2,830 | - | - | Class A Common Stock | ||
| Sera Prognostics Inc (Class A) | Jay M. Moyes | Chief Financial Officer | 19 Jul 2021 | 375 | 0 | - | - | Series B-1 Preferred Stock | ||
| Puma biotech Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 27,858 | 34,180 (0%) | 0% | 0 | Common Stock | |
| BioCardia Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 12,434 | 16,355 | - | - | Stock Option (right to buy) | |
| Puma biotech Inc | Jay M. Moyes | Director | Sale of securities on an exchange or to another person at price $ 11.36 per share. | 10 Jun 2021 | 25,248 | 6,322 (0%) | 0% | 11.4 | 286,860 | Common Stock |
| Achieve Life Sciences Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 3,750 | 3,750 | - | - | Stock Option (right to buy) | |
| BioCardia Inc | Jay M. Moyes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 3,456 | 54,267 (0%) | 0% | 0 | Common Stock |